MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2017 International Congress

    Spiral Analysis is a Promising Biomarker in LRRK2 G2019S carriers

    R. Ortega, M. Pullman, A. Glickman, I. Perera, M. San Luciano, A. Mirelman, C. Pont-Sunyer, N. Giladi, E. Tolosa, Q. Yu, S. Bressman, S. Pullman, R. Saunders-Pullman (New York, NY, USA)

    Objective: To assess whether harboring a LRRK2 G2019S mutation is associated with abnormalities in spiral drawing, including in mutation carriers with Parkinson Disease (PD) as…
  • 2017 International Congress

    Screening of GBA and LRRK2 G2019S Mutations in Egyptian Parkinson’s Disease Patients

    L. R'Bibo, S. Hamed, H. Houlden, N. Wood (London, United Kingdom)

    Objective: We aim to estimate the frequency of mutations in the glucocerebrosidase gene (GBA) and LRRK2 G2019S in a yet unstudied Egyptian Parkinson's disease population from the…
  • 2017 International Congress

    Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease

    L. Correia Guedes, S. Reimão, P. Paulino, R. Nunes, R. Bouça, D. Abreu, N. Gonçalves, T. Soares, M. Fabbri, C. Godinho, P. Lobo, D. Neutel, M. Quadri, M. Coelho, M.M. Rosa, J. Campos, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

    Objective: Our study aimed to evaluate neuromelanin-Magnetic Resonance signal changes in PD patients carrying a LRRK2 mutation. Background: Specific magnetic resonance (MR) sequences are able to…
  • 2017 International Congress

    Data driven analysis for exploring phenotypic differences in patients with Parkinson’s disease with or without genetic mutations.

    A. Mirelman, T. Kozlovski, A. Thaler, A. Mitelpunkt, T. Gurevich, M. Kestenbaum, Z. Gan Or, M. Gana-Weisz, A. Bar-Shira, A. Orr-Urtreger, S. Bressman, K. Marder, M. Marcus-Kalish, Y. Benjamini, N. Giladi (Tel Aviv, Israel)

    Objective: To explore, using a data driven statistical analysis method, discriminating phenotype features of disease in a large group of patients with Parkinson’s disease (PD)…
  • 2017 International Congress

    Gene associated differences in pre-diagnostic symptoms of Parkinson’s Disease: a retrospective study

    S. Liu, Z. Zheng, Z. Gu, C. Wang, J. An, H. Ding, M. Zhou, H. Zhang, X. Dan, Y. Li, M. Cao, S. Cen, T. Mi, P. Chan (Beijing, China)

    Objective: To investigate whether glucocerebrosidase (GBA) L444P and leucine-rich repeat kinase 2 (LRRK2) G2385R and R1628P mutations are associated with different symptoms and manifesting patterns…
  • 2017 International Congress

    Motor and Nonmotor clinical phenotype in LRRK2 Parkinson’s disease patients: a Case-control study

    L. Correia Guedes, R. Bouça, N. Gonçalves, T. Soares, D. Abreu, M. Fabbri, M. Coelho, M.M. Rosa, M. Quadri, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

    Objective: Our study aimed to characterize and compare the clinical phenotype of LRRK2-PD patients with PD patients with no identified mutations. Background: The clinical phenotype…
  • 2017 International Congress

    Altered intrinsic brain functional connectivity in drug-naïve Parkinson’s disease with LRRK2 mutation

    Y. Hou, C. Luo, J. Yang, R. Ou, W. Song, Y. Chen, Q. Gong, H. Shang (Chengdu, China)

    Objective: This study aimed to compare the alterations in the cortico-striatal functional connectivity (FC) of drug-naïve Parkinson’s disease (PD) patients with the leucine-rich repeat kinase…
  • 2016 International Congress

    Detection of leucine-rich repeat kinase 2 in human biofluids

    E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

    Objective: To evaluate the presence of leucine-rich repeat kinase 2 (LRRK2) in human biosamples, including cerebrospinal fluid (CSF) and urine, as a first step towards…
  • 2016 International Congress

    A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers

    A. Thaler, N. Bregman, A. Mirelman, T. Gurevich, M. Gana-Weiss, A. Orr-Urtreger, T. Hendler, N. Giladi (Tel-Aviv, Israel)

    Objective: To assess the cognitive profile of non-manifesting carriers of GBA and LRRK2 mutations using two fMRI tasks: a Stroop interference and N-Back working memory…
  • 2016 International Congress

    Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity

    C.H. Lin, H.I. Lin, M.L. Chen, T.T. Lai, L.P. Cao, M.J. Farrer, R.M. Wu, C.T. Chien (Taipei, Taiwan)

    Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley